Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07318051 · ClinicalTrials.gov registry record

Sample Collection for Ongoing Research and Product Evaluation Study

A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Natera.

Recruiting
Registry status
9,600
Enrollment target
1
Study location

NCT07318051 is a study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by Natera. The registered enrollment target is 9,600 participants, above the 2,795-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (243% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07318051, a study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by Natera.

RECRUITING
Registry status
9,600 participants
Enrollment target
1
Study location

Study Summary

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.

Study Locations (1)

Texas

  • Natera, Inc. - Austin

Trial Details

FieldValue
Enrollment Target 9,600 participants
Start Date 2025-07-21
Est. Completion 2035-01

Sponsor

Natera

27 total trials

What the Registry Record Tells You About NCT07318051

The ClinicalTrials.gov registry entry for NCT07318051 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 9,600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,795-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (243% higher). The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT07318051 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT07318051 about?

NCT07318051 is a clinical study titled "Sample Collection for Ongoing Research and Product Evaluation Study". The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's mo...

What is the current status of trial NCT07318051?

This trial is currently recruiting. The enrollment target is 9,600 participants. The study started on 2025-07-21. Estimated completion is 2035-01.

What conditions does trial NCT07318051 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer.

Who is sponsoring clinical trial NCT07318051?

This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07318051 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.